1,119 results match your criteria Lymphoma Malignant Anaplastic Ki 1+


The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Sci Rep 2022 Jun 21;12(1):10488. Epub 2022 Jun 21.

Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Hubei, 430081, China.

CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). However, even second- generation anti-CD30 CAR T-cells with CD28 (28z) costimulatory domains failed to achieve the desired rate of complete responses. In the present study, we developed second-generation (CD28z) and third-generation (CD28BBz) CAR T-cells targeting CD30 and investigated their efficacy in vitro and in vivo. Read More

View Article and Full-Text PDF

CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies.

Arch Pathol Lab Med 2022 04;146(4):415-432

MD Anderson Cancer Center at Cooper, Department of Medicine, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey (Budak-Alpdogan).

Context.—: In the early 1980s, a monoclonal antibody termed Ki-1 was developed against a cell line derived from a patient with Hodgkin lymphoma. This antibody detected a limited number of benign activated lymphocytes in lymphoid tissue, whereas in Hodgkin lymphoma it appeared to be nearly specific for Reed-Sternberg cells and their mononuclear variants. Read More

View Article and Full-Text PDF

Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.

Cells 2022 02 9;11(4). Epub 2022 Feb 9.

Division of Dermatology, McGill University, Montreal, QC H4A 3J1, Canada.

Cutaneous T cell lymphoma (CTCL) is a spectrum of lymphoproliferative disorders caused by the infiltration of malignant T cells into the skin. The most common variants of CTCL include mycosis fungoides (MF), Sézary syndrome (SS) and CD30 Lymphoproliferative disorders (CD30 LPDs). CD30 LPDs include primary cutaneous anaplastic large cell lymphoma (pcALCL), lymphomatoid papulosis (LyP) and borderline CD30 LPD. Read More

View Article and Full-Text PDF
February 2022

Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.

J Med Econ 2022 Jan-Dec;25(1):324-333

Health Economics Outcomes Research, Seagen Inc., Bothell, WA, USA.

Aims: To support reimbursement requests in Canada, we evaluated the cost-effectiveness of brentuximab vedotin (Adcetris) in combination with cyclophosphamide, doxorubicin, and prednisone (A + CHP) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as frontline treatment for CD30-expressing peripheral T-cell lymphomas (PTCLs) using results from the ECHELON-2 clinical trial. The PTCL subtypes included were systemic anaplastic large cell lymphoma (sALCL), PTCL-not otherwise specified (PTCL-NOS), and angioimmunoblastic T-cell lymphoma (AITL).

Materials And Methods: A partitioned survival model consisting of three health states (progression-free survival [PFS], post-progression survival [PPS], and death) was constructed from the perspective of the Canadian publicly funded healthcare system over a lifetime horizon. Read More

View Article and Full-Text PDF

Utility of a new notation to visualize flow cytometry analysis results: first preliminary comparison with immunohistochemistry to detect CD30 expression on T-cell lymphoma cells.

BMC Cancer 2021 Dec 20;21(1):1352. Epub 2021 Dec 20.

Division of Hematopathology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Background: It is important to confirm CD30 expression in T-cell lymphoma cases, but immunohistochemical staining for CD30 is not commonly performed and no comparison has been done between the results of flow cytometry (FCM) and immunohistochemical staining for CD30. Therefore, we devised a notation that we termed proportion of immunoreactivity/expression for FCM (PRIME-F notation), based on the cellular proportion showing different antigen-antibody reactivity.

Methods: We retrospectively compiled 211 cases of T-cell lymphoma, assessed via FCM, from major hospitals in Miyagi Prefecture from January 2012 to January 2019, and compared 52 of these cases with the immunohistochemical immunoreactive (IR) pattern of CD30 (PRIME-I notation). Read More

View Article and Full-Text PDF
December 2021

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.

Ann Oncol 2022 03 16;33(3):288-298. Epub 2021 Dec 16.

Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, NIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust, Manchester, UK.

Background: For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) exhibited statistically superior progression-free survival (PFS) per independent central review and improvements in overall survival versus CHOP for the frontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PTCL.

Patients And Methods: ECHELON-2 is a double-blind, double-dummy, randomized, placebo-controlled, active-comparator phase III study. Read More

View Article and Full-Text PDF

BIA-ALCL diagnosis on CytoLyt fixed ThinPrep, cell block and immunohistochemistry.

Diagn Cytopathol 2022 Jan 8;50(1):E1-E5. Epub 2021 Oct 8.

Department of Pathology and Cell Biology, Columbia University, New York City, New York, USA.

Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) is an emergent rare T cell non-Hodgkin lymphoma arising in association with a breast implant, particularly textured ones. Recent guidelines list cytopathological examination as the first essential step for diagnosis, routinely followed by CD30 immunohistochemistry (IHC) and flow cytometry (FC) for a T cell clone. The majority of BIA-ALCL literature regarding cytopathological evaluation describes morphology based on various preparation methods limited to cytospins and smears with the exception of at least one case report detailing cytomorphological and IHC findings on ThinPrep. Read More

View Article and Full-Text PDF
January 2022

Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.

Nat Commun 2021 09 22;12(1):5577. Epub 2021 Sep 22.

Division of Haematopathology, European Institute of Oncology IRCCS, Milan, Italy.

Anaplastic large cell lymphoma (ALCL), an aggressive CD30-positive T-cell lymphoma, comprises systemic anaplastic lymphoma kinase (ALK)-positive, and ALK-negative, primary cutaneous and breast implant-associated ALCL. Prognosis of some ALCL subgroups is still unsatisfactory, and already in second line effective treatment options are lacking. To identify genes defining ALCL cell state and dependencies, we here characterize super-enhancer regions by genome-wide H3K27ac ChIP-seq. Read More

View Article and Full-Text PDF
September 2021

Better method for detection of CD30: Immunohistochemistry or flow cytometry?

J Clin Exp Hematop 2021 Dec 10;61(4):221-223. Epub 2021 Sep 10.

Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

We compared the two methods of assessing CD30 protein expression in DLBCL and TCL specimens routinely employed at our hospital, immunohistochemistry (IHC) and flow cytometry (FCM), using the same clone of the anti-CD30 antibody (Ber-H2) in 123 patients with DLBCL and 28 patients with TCL. FCM was more sensitive than IHC, especially in cases with low expression. In three cases of TCL and two cases of DLBCL, there was discordance between these two methods. Read More

View Article and Full-Text PDF
December 2021

Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report.

Int J Dermatol 2022 Jul 7;61(7):e267-e269. Epub 2021 Aug 7.

Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.

View Article and Full-Text PDF

ALK-negative anaplastic large cell lymphoma, null type with aberrant expression of PAX5 and CD138: A diagnostic pitfall.

Diagn Cytopathol 2021 Oct 30;49(10):E395-E399. Epub 2021 Jun 30.

Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.

A 72-year-old man was found to have generalized lymphadenopathy, splenomegaly, and elevated serum lactate dehydrogenase. Fine-needle aspiration and core needle biopsy of a cervical lymph node revealed a large lymphoid cell proliferation with features suggestive of anaplastic large cell lymphoma (ALCL). However, immunophenotypically, the neoplastic cells expressed PAX5 and CD138 in addition to CD30, CD45, MUM-1 and were negative for T-cell markers, B-cell markers, CD15, ALK-1, HHV-8, EBER, kappa, lambda, and pancytokeratin. Read More

View Article and Full-Text PDF
October 2021

What's new in peripheral T-cell lymphomas.

Hematol Oncol 2021 Jun;39 Suppl 1:52-60

Surgical, Medical and Dental Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Reggio Emilia, Italy.

Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of hematological malignancies with extremely poor prognosis for almost all subtypes. The diverse clinicopathological features of PTCLs make accurate diagnosis, prognosis, and choice of optimal treatment strategies difficult. Moreover, the best therapeutic algorithms are still under debate due to the extrapolated approaches developed for B-cell lymphomas and to the absence of few treatment protocol specifically developed for PTCLs. Read More

View Article and Full-Text PDF

JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.

Am J Surg Pathol 2021 07;45(7):895-904

Department of Pathology, Massachusetts General Hospital, Harvard Medical School.

Peripheral T-cell lymphoma (PTCL) comprises a heterogenous group of rare mature T-cell neoplasms. While some PTCL subtypes are well-characterized by histology, immunophenotype, and recurrent molecular alterations, others remain incompletely defined. In particular, the distinction between CD30+ PTCL, not otherwise specified and anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma can be subject to disagreement. Read More

View Article and Full-Text PDF

Nonmalignant CD30+ Cells in Contralateral Peri-Implant Capsule of Patient With BIA-ALCL: A Premalignant Step?

Aesthet Surg J 2022 01;42(2):NP125-NP129

Department of Medicine, Brown University Alpert Medical School, Providence, RI, USA.

CD30 lymphocyte activation antigen and phosphorylated STAT3 (pSTAT3) are consistent markers of tumor cells in breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). We present a case of BIA-ALCL in a breast implant capsule containing clustered tumor cells expressing CD30, pSTAT3, pSTAT6, interleukin 9, and granzyme B tumor cell biomarkers. Remarkably, the contralateral breast contained many scattered large, atypical CD30+ cells surrounded by inflammatory cells, raising a suspicion of bilateral BIA-ALCL, known to occur in some patients. Read More

View Article and Full-Text PDF
January 2022

Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.

Semin Hematol 2021 04 6;58(2):85-94. Epub 2021 Mar 6.

Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, IL. Electronic address:

Peripheral T-cell lymphomas (PTCL) are rare lymphoproliferative disorders with poor outcomes and high rates of relapse. Incidence varies although the most common subtypes include PTCL-not-otherwise specified, anaplastic large cell lymphoma, and angioimmunoblastic T-cell lymphoma. Anaplastic large cell lymphoma is characterized by near-universal CD30 expression and serves as a prototypic model for other CD30-expressing lymphomas. Read More

View Article and Full-Text PDF

Pediatric primary cutaneous anaplastic large cell lymphoma treated with brachytherapy.

Pediatr Dermatol 2021 May 19;38(3):712-713. Epub 2021 Mar 19.

Dermatology Program, Boston Children's Hospital, Boston, MA, USA.

Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder that rarely occurs in children. Although there are currently no consensus guidelines for the treatment of cutaneous lymphoma in the pediatric population, the isolated form of PC-ALCL is typically managed by surgical excision or external beam radiation therapy. We report the case of a 6-year-old girl with primary cutaneous anaplastic large cell lymphoma that was treated with brachytherapy with no recurrence after 21 months of follow-up, suggesting that brachytherapy may be considered as a treatment for pediatric cutaneous large cell anaplastic lymphoma. Read More

View Article and Full-Text PDF

Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?

Virchows Arch 2021 Aug 18;479(2):377-383. Epub 2021 Feb 18.

Department of Pathology, Dermatopathology Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Mycosis fungoides with large cell transformation (MFLCT) can be difficult to distinguish from primary cutaneous CD30+ T cell lymphoproliferative disorders (PC CD30+ LPD), especially primary cutaneous anaplastic large cell lymphoma (PC-ALCL). This diagnostic distinction is critical for appropriate patient management. GATA3 has been proposed to be useful in the discrimination between these two entities. Read More

View Article and Full-Text PDF

A case of lymphomatoid papulosis type E in a young adult: An uncommon entity.

J Cutan Pathol 2021 May 18;48(5):694-700. Epub 2021 Feb 18.

Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA.

Lymphomatoid papulosis (LyP) type E is a rare variant of the primary cutaneous CD30+ lymphoproliferative disorders, characterized clinically by large necrotic eschar-like lesions and histopathologically by angiodestructive and angioinvasive infiltrates of CD30+ lymphocytes. As in other forms of lymphomatoid papulosis, type E lesions may undergo spontaneous regression after weeks, with frequent recurrences. We report a 21-year old male with an angiodestructive infiltrate of CD30+ lymphocytes manifesting as a papular eruption rather than ulceration, and suggest that this clinical phenotype might be related to the presence of CD4+ lymphocytes in the inflammatory cell infiltrate. Read More

View Article and Full-Text PDF

Primary cutaneous neutrophil-rich anaplastic large-cell lymphoma showing self-regression: the role of IL-8-regulated neutrophils.

Eur J Dermatol 2020 Oct;30(5):596-597

Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, 36 Nishi-cho, Yonago 683-8504, Japan.

View Article and Full-Text PDF
October 2020

Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.

J Oncol Pharm Pract 2021 Oct 25;27(7):1730-1735. Epub 2020 Oct 25.

Pharmacy Department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, Toulouse, France.

Introduction: Brentuximab vedotin (Bv) has been approved for the treatment of Refractory/Relapsed (R/R) Anaplastic Large Cell Lymphomas (ALCL) and cutaneous T-Cell Lymphomas, but is also effective in other CD30+ malignancies. We report here the outcomes of patients with various R/R Peripheral T Cell Lymphoma (PTCL) treated with Bv in real life practice.

Method: This was a retrospective, single-center study based on medical records of patients with R/R PTCL treated either with Bv alone or in combination with chemotherapy. Read More

View Article and Full-Text PDF
October 2021

Primary cutaneous anaplastic large-cell lymphoma of the eyelid: report of two cases and review of the literature.

Orbit 2021 Dec 1;40(6):481-487. Epub 2020 Oct 1.

Department of Neurosciences, Reproductive Sciences and Dentistry, University of Naples Federico II, Naples, Italy.

Purpose: Two new cases of primary cutaneous CD30+ anaplastic large-cell lymphoma (cALCL) of the eyelid are reported; these are analysed alongside existing cases to identify challenges relating to the diagnosis and management of such rare lesions.

Material And Methods: A review of existing literature on the PubMed database is conducted using the keywords: 'eyelid lymphoid proliferations', 'lymphoma of the eyelid', and 'primary cutaneous CD30+, ALK-anaplastic large-cell lymphoma of the eyelid'. Two new cases of cALCL are reported. Read More

View Article and Full-Text PDF
December 2021

Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma.

Cytometry B Clin Cytom 2021 07 17;100(4):488-496. Epub 2020 Aug 17.

Laboratoire d'Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse, France.

CD30 transmembrane receptor, a member of the tumor necrosis factor receptor family, is expressed in different lymphomas. Brentuximab vedotin (BV), a CD30 monoclonal antibody (Ab)-drug conjugate, is effective in CD30-positive lymphomas. However, the response to BV is not always correlated to CD30 expression detected by immunohistochemistry (IHC). Read More

View Article and Full-Text PDF

CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.

Br J Cancer 2020 09 20;123(7):1101-1113. Epub 2020 Jul 20.

Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW, Australia.

Background: Epithelioid inflammatory myofibroblastic sarcoma (eIMS) is characterised by perinuclear ALK localisation, CD30 expression and early relapse despite crizotinib treatment. We aimed to identify therapies to prevent and/or treat ALK inhibitor resistance.

Methods: Malignant ascites, from an eIMS patient at diagnosis and following multiple relapses, were used to generate matched diagnosis and relapse xenografts. Read More

View Article and Full-Text PDF
September 2020

Primary central nervous system ALK-positive anaplastic large cell lymphoma with CD56 abnormally expression in a Chinese child: Challenge in diagnostic practice.

Int J Immunopathol Pharmacol 2020 Jan-Dec;34:2058738420941756

Department of Pathology, West China Hospital of Sichuan University, Chengdu, China.

Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALK + ALCL) is most frequent in youth and possesses a broad morphologic spectrum. However, involvement in central nervous system (CNS) is definitely rare. The case we presented was a 12-year-old Chinese male who presented with headache and emesis for a couple of days. Read More

View Article and Full-Text PDF

Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.

Curr Hematol Malig Rep 2020 08;15(4):333-342

City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA.

Purpose Of Review: Primary cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPDs) are the second most common cutaneous lymphomas after mycosis fungoides and Sezary syndrome. They include primary cutaneous anaplastic large cell lymphoma (pcALCL), lymphomatoid papulosis (LyP), and borderline lesions. The purpose of this literature review is to consolidate the available evidence on the primary cutaneous CD30+ LPD in order to define the tools for correct diagnosis and appropriate treatment. Read More

View Article and Full-Text PDF

Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.

Br J Haematol 2021 01 19;192(1):82-99. Epub 2020 May 19.

Hematology Department, Fundación Jiménez Díaz, Madrid, CIBERONC, Madrid, Spain.

We investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo Italiano Linfomi system, treatments, and clinical outcomes were examined. A sizeable proportion of 175 patients had a history of immune-related disorders (autoimmune 16%, viral infections 17%, chemo/radiotherapy-treated carcinomas 19%). Read More

View Article and Full-Text PDF
January 2021

The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma.

J Am Acad Dermatol 2021 Jan 22;84(1):185-187. Epub 2020 Apr 22.

Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne; Faculty of Medicine, Nursing, and Health Sciences, Monash University, Clayton; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. Electronic address:

View Article and Full-Text PDF
January 2021